Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4762 - Expression of estrogen receptors and beta-III tubulin in non-small cell lung cancer tissue

Date

11 Sep 2017

Session

Poster display session

Presenters

Evgeniya Ponomarenko

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

E. Ponomarenko1, I. Mamichev1, T.A. Bogush2, O.M. Ryabinina2, J.B. Dyakova1, D. Novikov2, B.E. Polotsky2, M.M. Davydov3

Author affiliations

  • 1 Laboratory Of Medical Chemistry, N.N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2 Laboratory Of Medical Chemistry, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 3 Thoracic Surgery Department, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
More

Resources

Abstract 4762

Background

Estrogen receptors beta (ERβ) are highly expressed in different normal and neoplastic tissues that, until recently, has been considered to be ER-negative based on ERα expression evaluation. Among the genes, regulated via estrogen signaling there is one, coding microtubule protein beta-III tubulin (TUBB3). TUBB3 expression is found in many solid tumors and is linked to poor prognosis and resistance to taxanes. Since it is little known about mechanisms behind TUBB3 expression in non-small cell lung cancer (NSCLC), we decided to find out if there is a correlation between ER and TUBB3 expression in this type of cancer.

Methods

104 surgical samples of NSCLC were converted to single-cell suspension, stained with primary anti-ERα (abSP-1), anti-ERβ (ab14C8), anti-TUBB3 (ab7751) antibodies and secondary fluorescent antibodies. Immunofluorescent estimation was performed using flow cytometry. Expression level was determined as the ratio (%) of specifically fluorescent cells to the number of cells stained with secondary antibodies. Spearman rank correlation was used to test the association between variables.

Results

Both ER were revealed in all NSCLC specimens. Mean expression level of ERβ was significantly higher compared with ERα (46,6 ± 17,0% vs 23,2 ± 14,2%, respectively). Mean TUBB3 expression level was 43,1±15,7%. In all the tumors investigated only weak correlation observed between and ER status and TUBB3 expression level (rs = 0,3 and rs = 0,4 for ERα and ERβ, respectively). In the group of squamous cell cancer specimens (n = 68) the association was strong (rs = 0,5 and rs = 0,5 for ERα and ERβ, respectively). In the group of adenocarcinoma specimens (n = 36) the correlation between ERα and TUBB3 was very weak (rs = 0,3) and there was no correlation between ERβ and TUBB3.

Conclusions

1. Strong correlation between TUBB3 and ER expression was found only in squamous cell cancer tissue. 2. The dominant type of estrogen receptors is ERβ. 3. In clinical terms high ERβ expression means that in case of resistance to standart platinum/taxane duplets, patients with high tumor ERβ expression may benefit from antiestrogen therapy. Supported by RFBR grants (№№15-04-06991-а, 16-34-01049-mol-a) and grant of the President of RF МК-7709.2016.7.

Clinical trial identification

Legal entity responsible for the study

N.N. Blokhin Russian Cancer Research Center.

Funding

Russian Foundation for Basic Research Grants, grant of the President of Russian Federation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.